Frontlight ResearchEarly access
WithdrawnNo phase
The Usefulness of Coronary CT Scan After Everolimus-eluting Bioabsorbable Scaffold Implantation for Coronary Artery Disease
Key facts
- Who runs it
- Jung-min Ahn
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- Dec 2021
- Ended
- Dec 2023
- Type of study
- Observational
- Treatments tested
- Computed tomographic scan
- Record updated
- 23 July 2021
- Why it stopped
- This study will be revived with retrospective design.
Who can take part
- Age
- 19 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Patients treated withBioresobable Vascular Scaffold for coronary disease
Who cannot take part
- History of allergy to contrast
- Severe arrhythmia
- Serum Creatinine > 2.0 mg/dl
- Pregnancy or breast feeding
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to evaluate usefulness of coronary computed tomographic scan for prediction of clinical events after everolimus-eluting bioabsorbable scaffold implantation for coronary artery disease.
The group in the trial
- bioabsorbable scaffold
Patients with BVS(bioabsorbable scaffold) for coronary stenosis
Treatment: Computed tomographic scan
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Usefulness of Coronary CT Scan After Everolimus-eluting Bioabsorbable Scaffold Implantation for Coronary Artery Disease; A Single Center, Prospective Observational Study
- Record updated
- 23 July 2021